Pharma and Biotech M&A Trends 2009-2014

ReportLinker Find Industry reports, Company profilesand Market Statistics

>> Get this Report Now by email!

Pharma and Biotech M&A Trends 2009-2014

Published on July 2014

Report Summary

The Pharma and Biotech M&A Trends 2009-2014 report provides comprehensive understanding and unprecedented access to the

merger and acquisition agreements entered into by the worlds leading biopharma companies. The report provides a detailed

understand and analysis of how and why companies enter merger and acquisition deals.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in

terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the

payments clauses, the devil is in the detail in terms of how payments are triggered ' contract documents provide this insight where

press releases and databases do not.

This report contains a comprehensive listing of all merger and acquisition deals announced since 2009 as recorded in the Current

Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual merger and

acquisition contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important

issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of M&A dealmaking and business activities. Chapter 1 provides an introduction

to the report, whilst chapter 2 provides an analysis of the trends in M&A as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of M&A deals. The chapter includes numerous case studies to enable understanding

of M&A deals.

Chapter 4 provides a review of the leading M&A deals since 2009. Deals are listed by headline value, signed by bigpharma and and

most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online

access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 50 big pharma companies (with M&A announements) with a brief summary

followed by a comprehensive listing of M&A deals available in the public domain. Where available, each deal title links via Current

Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each

contract document on demand.

Chapter 6 provides a comprehensive listing of the top 50 big biotech companies (with M&A announements) with a brief summary

followed by a comprehensive listing of M&A deals available in the public domain. Where available, each deal title links via Current

Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each

contract document on demand.

Chapter 7 provides a comprehensive and detailed review of M&A deals signed and announced since 2009 where a contract

document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with

respect to the M&A deal.

Pharma and Biotech M&A Trends 2009-2014 (From Issuu) Page 1/21

http://www.reportlinker.com?utm_campaign=plp&utm_source=issuu&utm_medium=referral



http://www.reportlinker.com/p02225955/Pharma-and-Biotech-M&A-Trends-2009-2014.html#utm_campaign=plp&utm_source=issuu&utm_medium=referral




In addition the report includes a comprehensive listing of all M&A deals announced since 2009. Each listing is organized as an

appendix by company A-Z, and industry sector. Each deal title links via hyperlink to an online version of the deal record including,

where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in M&A dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about M&A alliances.

Table of Content

TABLE OF CONTENTS

Executive Summary

Chapter 1 ' Introduction

Chapter 2 ' Trends in M&A dealmaking

2.1. Introduction

2.2. Difference between merger and acquisition deals

2.3. Trends in M&A deals since 2009

2.3.1. Japanese M&A accelerates

2.3.2. Option to acquire the new acquisition'

2.3.3. Case study 1: Cephalon ' Ception

2.3.4. Case study 2: HertArt Aps ' Vitrolife

2.4. When M&A can be useful

2.5. Attributes of M&A deals

2.5.1. M&A as an alternative to IPO

2.6. Partnering deals with M&A component

2.6.1. Partnering as a precursor to M&A

2.6.1.a. Case study 3: Celgene ' VentiRx Pharmaceuticals, Oct 2012

2.6.2. Equity as part of partnering deal

2.6.2.a. Case study 4: BioMarin ' Catalyst Pharma Partners, Oct 2012

2.6.2.b. Case study 5: Pfizer ' Clovis Oncology , June 2011

2.6.2.c. Case study 6: Tesaro ' OPKO Health, December 2010

2.6.3. Conversion of partnership to acquisition

2.6.4. But M&A is not always the route followed

2.7. Big pharma mega mergers ' are we at the end of the road'

2.7.1. Growth of Johnson & Johnson through M&A

2.7.2. Growth of Novartis through M&A

2.8. Accessing innovation through M&A

2.8.1. Big pharma acquisitions of small companies

2.8.1.a. Case study 7: Abbott ' Facet Biotechnology

2.8.1.b. Case study 8: Gilead Sceinces ' Pharmasset

2.8.2. Medium and small biopharma ' use of M&A

2.8.2.a. Case study 9: Allergan ' MAP Pharmaceuticals

2.8.2.b. Case study 10: Reckitt Benckiser ' Schiff Nutrition International

2.8.3. Using M&A to build a company

2.8.3.a. Case study 11: Shire ' built from M&A









2.8.3.b. Case study 12: Zeneus - acquiring a ready-made European capability

2.8.3.c. Case study 13: Novartis ' from pure pharma to half generic

2.8.4. Emergence of biotech-biotech mergers

2.8.4.a. Case study 14: Merger between Biogen and Idec

2.8.4.b. Case study 15: Amgen acquisition activity

2.9. The emerging role of private equity in M&A

2.10. Implementing M&A transactions

2.11. Joint ventures as alternative to M&A

2.12. The future of M&A in biopharma

Chapter 3 ' Overview of M&A deal structure

3.1. Introduction

3.2. Pure versus multi-component acquisition deals

3.3. Pure M&A agreement structure

3.3.1. Example acquisition agreements

3.3.1.a. Case study 16: Allergan - SkinMedica ' November 2012

3.4. Acquisition as part of a wider alliance agreement

3.4.1. Example acquisition option clauses

3.4.1.a. Case study 17: MGI Pharma ' AkaRx ' October 2007

3.5. Merger agreements

3.5.1. Example merger agreements

3.5.1.a. Case study 18: Synergy Pharmaceuticals ' Callisto Pharmaceuticals ' July 2012

Chapter 4 ' Leading M&A deals

4.1. Introduction

4.2. Top M&A deals by value

4.3. Top merger deals

4.4. Most active M&A dealmakers

4.5. Big pharma M&A deal activity

4.6. Big biotech M&A deal activity

Chapter 5 ' Big pharma M&A deals

5.1. Introduction

5.2. How to use M&A deals

5.3. Big pharma company M&A deal profiles

Abbott

Abbvie

Actavis

Allergan

Amgen

Aspen Pharmacare

Astellas

AstraZeneca

Baxter International

Bayer









Biogen Idec

Boehringer Ingelheim

Bristol-Myers Squibb

Celgene

Daiichi Sankyo

Dainippon Sumitomo

Eisai

Eli Lilly

Endo Pharmaceuticals

Forest Laboratories

Fresenius

Gilead Sciences

GlaxoSmithKline

Grifols

Hospira

Johnson & Johnson

Kyowa Hakko Kirin

Lundbeck

Menarini

Merck & Co

Merck KGaA

Mitsubishi Tanabe

Mylan

Novartis

Otsuka

Pfizer

Roche

Sanofi

Servier

Shionogi

Shire

Sun Pharmaceutical

Takeda

Teva

UCB

Valeant

Chapter 6 ' Big biotech M&A deals

6.1. Introduction

6.2. How to use M&A deals

6.3. Big biotech company M&A deal profiles

3SBio

Acorda Therapeutics

Actelion

Alexion Pharmaceuticals

Alkermes

AMAG Pharmaceuticals

Anika Therapeutics

Bavarian Nordic









Biocon

BioMarin Pharmaceuticals

Cangene

Celgene

Cubist

Elan

Emergent BioSolutions

Enzo Biochem

Galapagos

Ipsen

Isis Pharmaceuticals

LFB Group

Morphosys

Onyx Pharmaceuticals

Optimer

Questcor Pharmaceuticals

SciClone Pharmaceuticals

Spectrum Pharmaceuticals

Swedish Orphan Biovitrum

The Medicines Company

United Therapeutics

Vertex Pharmaceuticals

ViroPharma

Chapter 7 ' M&A contracts directory

7.1. Introduction

7.2. Company A-Z

Abbott Laboratories

Abbvie

Abraxis BioScience

Abraxis Health

Accelerated Care Plus

AccelPath

Accelrys

Accuray

Acon Labs

Acorda Therapeutics

Actavis

Actavis (acquired by Watson)

Actinium Pharmaceuticals

Adamis Pharmaceuticals

Adeona Pharmaceuticals

Adolor

Advanced Biohealing

Advanced Medical Optics

Adventrx Pharmaceuticals

Aetna

AGA Medical

Agila Specialties









Agilent Technologies

Akorn

Albany Molecular Research

Aldagen

Alexion Pharmaceuticals

Alexza Pharmaceuticals

Alkermes

Allergan

Allezoe Medical

Allos Therapeutics

Allozyne

Alpha Innotech

Alphatec Spine

Alpine Biomed

Amag Pharmaceuticals

Amarin

American Medical Systems

Amerifit Brands

Amgen

Amorcyte

Amsterdam Molecular Therapeutics

Amylin Pharmaceuticals

Anchen Pharmaceuticals

Anesiva

ANI Pharmaceuticals

Anika Therapeutics

AorTx

Apax Partners

Applied Genomics

Aptalis Pharma

Apthera

AquaMed Technologies

Arcion Therapeutics

Ardea Biosciences

Arigene

Ariston Pharmaceuticals

Arrayit Diagnostics

Arresto BioSciences

Arrow Group

Arthrocare

Asahi Kasei

Ashland

Aspect Medical Systems

Assay Designs

AssuraMed

Astellas Pharma

Astex Pharmaceuticals

Astex Therapeutics









Astra Tech

AstraZeneca

Atlas Acquisition Corp

ATS Medical

Aurora Diagnostics

Avalon Pharmaceuticals

AVANYX Therapeutics

Avista Capital Partners

AxoGen

Azur Pharma

Banner Health

Bausch & Lomb

Baxter International

Bayer Healthcare

BBC Graphics

Beckman Coulter

Beijing Genomics Institute (BGI)

Belgian Volition

Bio-Imaging Technologies

BioClinica

Biocompatibles International

BioCryst Pharmaceuticals

Bioform Medical

BioMarin Pharmaceutical

BioMimetic Therapeutics

Bioniche Pharma

BioReliance

BioSante Pharmaceuticals

BioScrip

BioSphere Medical

Biotel

BioTelemetry

BioTime

Biovail

BioVectra

Biovex

Blackstone Lake Minerals

Bohai Pharmaceuticals Group

Boston Therapeutics

Bristol-Myers Squibb

BTG

Byrne Medical

Cactus Ventures

Cadence Pharmaceuticals

Cahaba Pharmaceuticals

Caleco Pharma

California Stem Cell

Caliper Life Sciences









Calistoga Pharmaceuticals

Calixa Therapeutics

Callisto Pharmaceuticals

Cambrex

Cambrex Zenara

Cambridge Research and Instrumentation

Canada Pension Plan Investment Board

Candela

Cantel Medical

Cape Cod Cardiac Cath

Cape Cod Cardiology Services

Cape Cod Hospital

Caraco Pharmaceuticals

Cardiac Science

Cardinal Health

CardioCORE Lab

Cardiogenesis

Cardiokine

Cardo Medical

CareDx

Celera

Celgene

Cell Biosciences

Cell Genesys

Cell Therapeutics

Celldex Therapeutics

Cellectar Biosciences

Cephalon

Ception Therapeutics

Cequent Pharmaceuticals

Cesca Therapeutics

Charles River Laboratories

Charterhouse Equity Partners

Chief Respect

Chiesi Farmaceutici

China Biopharmaceuticals

China Medicine Corporation

China PharmaHub

CitySync

Clarient

Claros Diagnostics

Clinical Data

CNS Wellness

CombinatoRx

Commonwealth Biotechnologies

Complete Genomics

Conceptus

Conmed









Cornerstone Therapeutics

Cortex Pharmaceuticals

Cougar Biotechnology

Covella Pharmaceuticals

Coventry Health Care

Covidien

CPEX Pharmaceuticals

Crealta Pharmaceuticals

Critical Homecare Solutions

Crucell

Cryolife

Cubist Pharmaceuticals

Curacyte Discovery

Curagen

Curaxis Pharmaceuticals

CV Therapeutics

CyDex

Cypress Pharmaceutical

Cyrenaic Pharmaceuticals

Cytomedix

Cytopia

Dainippon Sumitomo Pharma

Dako

Danaher

Dentsply International

Denville Scientific

Derma Sciences

Dermik Laboratories

Diagnostic Hybrids

Dialysis Corp of America

DigiPath Solutions

Dionex

Divine Skin Laboratories

Dragon Pharmaceutical

DS Healthcare

DSM

DUSA Pharmaceuticals

Dynavax Technologies

EKR Therapeutics

Elan

Elan Drug Technologies

Eli Lilly

Emergent BioSolutions

Endo Pharmaceuticals

Endologix

Enobia Pharma

Enzo Biochem

Eon Labs









EpiCept

EQT

Ester Neurosciences

Etrials Worldwide

EUSA Pharma

Ev3

Excelsyn

Express Scripts

Facet Biotechnology

FasTrack Pharmaceuticals

Fero Industries

Fidia Advanced Biopolymers

Fidia Farmaceutici

FluoroPharma Medical

Footstar

Forest Laboratories

Forest Pharmaceuticals

Fujifilm

GE Healthcare

Gemin X Pharmaceuticals

Gen-Probe

Genentech

Generex Biotechnology

GeneSeek

GenturaDx

Genzyme

Gilead Sciences

GL Biochem

GlaxoSmithKline

Global Med Technologies

Global Medical Direct

Glycosan BioSystems

Grifols

GTC Biotherapeutics

Guangzhou LifeTech Pharmaceuticals

Haemonetics Corporation

Hanger Orthopedic Group

Hansen Medical

Hartlab

Harvard Bioscience

Hasco Medical

HealthTronics

Heart Hospital of Austin

HeartWare International

Hellman & Friedman

HepaLife

Hi-Tech Pharmacal

Hisamitsu Pharmaceutical









Hologic

Home Diagnostics

Hongshan Pharmaceuticals

Hospira

Human Genome Sciences

Huxley Pharmaceuticals

Hyaluron

Hypermarcas

I-Flow

Icagen

Idenix Pharmaceuticals

Ignyta

Illumina

Image Sensing Systems

ImaRX

IMMCO Diagnostics

Immucor

ImmuMetrix

Immune Pharmaceuticals

Immunovative Therapies

Impulse Monitoring

INC Research

Incline Therapeutics

Indevus Pharmaceuticals

Infinity Oil & Gas

Inhibitex

Innovus Pharmaceuticals

Inovio Biomedical

Insmed Inc

Inspire Pharmaceuticals

Intellipharmaceutics

International Specialty Products

InVentiv Health

Inverness Medical Innovations

InVivo

InVivo Therapeutics

ISTA Pharmaceuticals

Javelin Pharmaceuticals

Jazz Pharmaceuticals

Jefferies & Company

Johnson & Johnson

Juniper Investment Company

Kendle International

Kimberly-Clark

Kinetic Concepts

King Pharmaceuticals

Kinray

La Jolla Pharmaceutical









Laboratory Corporation of America

Lantis Laser

LEAD Therapeutics

LecTec

LEO Pharma

Lexicon Pharmaceuticals

LFB Biomedicaments

Life Technologies

Ligand Pharmaceuticals

Link Resources

Lipocine

LMA International

Luminex

MAKO Surgical

Mallinckrodt Pharmaceuticals

Manhattan Pharmaceuticals

Manhattan Scientifics

Mantecorp

MAP Pharmaceuticals

Martek Biosciences

Maya Medical

McKesson

MDRNA

Medarex

MedCath

Medco Health Solutions

MedEfficiency

Medical Developers

Medical Imaging

Medicis Pharma

MediVision Medical Imaging

MedServe

Medtox Scientific

Medtronic

Mepha Pharma

Merck and Co

Merck KGaA

Merge Healthcare

Merit Medical Systems

Merz

Metabasis Therapeutics

MIB Digital

Micro Beef Technologies

MicroFluidic Systems

Micromet

MidCap Financial

Millipore

Minerva Neurosciences









Monogram Biosciences

MorphoSys

Multigen Diagnostics

MWI Veterinary Supply

Mylan Laboratories

Myriad Genetics

Myriad Pharmaceuticals

Myriad RBM

Natus Medical

NBTY

Nellix

Neogen

NeoStem

Nepentes

Neurogen

Neuromed

Neuronex

NextRx

Nipro Corporation

North Horizon

Novartis

NovaVision

Novelos Therapeutics

Noven Pharmaceuticals

Novo Energies

NuPathe

Nurx Pharmaceuticals

NuVasive

Obagi Medical Products

Omthera Pharmaceuticals

One Lambda

Onyx Pharmaceuticals

Ophthalmic Imaging Systems

OPKO Health

Optimer Pharmaceuticals

Opto Circuits

Oracle Health Sciences

Orchid Cellmark

Orchid Chemicals and Pharma

Organ Transport Systems

Organovo

OrthoCyte

Orthohelix Surgical Designs

OSI Pharmaceuticals

Osteotech

Otix Global

Otsuka

OXiGENE









Paddock Laboratories

Papillon Holdings

Par Pharmaceutical

Parkway Clinical Laboratories

Pathfinder

Pathfinder Cell Therapy

PBM Products

Pearl Therapeutics

Penwest Pharmaceuticals

Peplin

PerkinElmer

Pernix Therapeutics

Perrigo

Pfizer

Phadia

Pharmasset

PharmaSwiss

PharmAthene

Phase Forward

PhotoMedex

Pier Pharmaceuticals

Piramal Healthcare

Poniard Pharmaceuticals

PositiveID

Power Medical Interventions

PPD

Presidio Pharmaceuticals

Prodesse

Progenitor Cell Therapy

Proteolix

Proximagen Group

Psynova Neurotech

Public Sector Pension Investment Board

Puma Biotechnology

Pyro Pharmaceuticals

QLT

Qualitest Pharmaceuticals

QuantRx Biomedical

Quest Diagnostics

Questcor Pharmaceuticals

Quidel

Radiancy

Radiation Therapy Services

Radius Health

Raptor Pharmaceutical

Reckitt Benckiser

Research Pharmaceutical Services

Roche









Rosetta Genomics

Rules-Based Medicine

RXi Pharmaceuticals

Safeguard Scientifics

Sanofi-Aventis

Sanofi

Santarus

Savient Pharmaceuticals

Schering-Plough

Schiff Nutrition International

Scientific Nanomedicine

Scientx

Senior Scientific

Sepracor

Shire Pharmaceuticals

Sight Science

Sigma-Aldrich

Sirius Laboratories

SkinMedica

Sloning BioTechnology

Smith & Nephew

Solta Medical

Solvay

Somanetics

Somaxon Pharmaceuticals

Sonkei Pharmaceuticals

Sonora Medical Systems

SonoSite

Southern Medical Acquisition

Southern Medical and Mobility

Spear Pharmaceuticals

Specifar Pharma

Spectrum Pharmaceuticals

SRI Surgical Express

St Jude Medical

Stericycle

Stryker

Sucampo AG

Sucampo Pharmaceuticals

Sun City Cardiac Center Associates

Sun Pharma Global

Sun Pharmaceutical

Sunovion Pharmaceuticals

SuperGen

Sycamore Films

Symphony Allegro

Symphony Capital

Symphony Dynamo









Symphony Icon

Symyx Technologies

Synageva BioPharma

Synergy Health

Synergy Pharmaceuticals

Syneron

Synovis Life Technologies

SyntheMed

Synthes

SynthRx

Systems Medicine

TAG Minerals

Talecris Biotherapeutics

Taligen Therapeutics

Tamandare Explorations

Targanta Therapeutics

Taro Pharmaceuticals

Teleflex

Tepnel Life Sciences

Teva Pharmaceutical Industries

The Carlyle Group

The Medicines Company

Theraclone Sciences

Theragenics

TherapeuticsMD

Thermo Fisher Scientific

ThermoGenesis

Thomas Medical

Thoratec

Tolmar

TomoTherapy

TONIX Pharmaceuticals

Tornier

TorreyPines Therapeutics

TotipotentRx

Tourtellotte Solutions

TPG Capital

Transave

Trimeris

Trinity Biotech

Trius Therapeutics

TrovaGene

Trubion

UniQure

Upsher-Smith

Urchin Merger Sub

US Oncology

Uteron Pharma









Valeant Pharmaceuticals

ValiRx

Varian Medical Systems

Vascular Solutions

Vasogen

VaxGen

VelQuest

Vertebron

Vertex Pharmaceuticals

VGX Pharmaceuticals

Vicept Therapeutics

Viking Systems

ViroChem Pharma

Viropharma

Visual Sonics

Vital Signs

VitamedMD

VNUS Medical Technologies

VolitionRX

Waban Software Group

Warburg Pincus

Warner Chilcott

Watson Pharmaceuticals

Wellness Center USA

Wellpoint

William Demant Holding

World Wide Relics

Wright Medical

WuXi PharmaTech

Wyeth

Yantai Tianzheng Pharmaceutical

YM BioSciences

Zenara Pharma

Zerusa

Zoll Medical

ZymoGenetics

ZyStor Therapeutics

7.3. By industry sector

Academic

Agricultural

Animal Health

Bigbiotech

Bigpharma

Biotech

Consumer health

Drug delivery

Medical device

Diagnostic









Financial

Generic pharma

Government

Non-profit

Pharmaceutical

Research tools

Services

Specialty pharma

About Wildwood Ventures

Current Partnering

Current Agreements

Recent report titles from Current Partnering

Upgrade Order Form ' Subscription Access Products

The following appendices are available in a accompanying volume.

Appendices

Appendix 1 ' Company A-Z

Appendix 2 ' By industry sector

Academic

Agricultural

Animal Health

Big pharma

Big biotech

Biotech

Consumer health

Drug delivery

Medical device

Diagnostic

Financial

Generic pharma

Government

Non-profit

Pharmaceutical

Research tools

Services

Specialty pharma

Appendix 3 ' M&A dealmaking references

Appendix 4 ' Resources

Appendix 5 ' Deal type definitions

Appendix 6 ' Example M&A contract document

TABLE OF FIGURES

Figure 1: Definition of merger and acquisition

Figure 2: Trends in M&A deal announcements, 2009-2014









Figure 3: M&A deals signed at each phase of development, 2009-2014

Figure 4: Key recent M&A trends ' 2009 to present

Figure 5: Recent Japanese M&A

Figure 6: Recent 'option to acquire' deals

Figure 7: Situations where M&A can prove useful

Figure 8: Recent partnering deals involving equity participation in the licensor

Figure 9: Equity investments converting to acquisitions

Figure 10: Johnson & Johnson's growth through M&A

Figure 11: Novartis's growth through M&A since 2000

Figure 12: Shire's M&A history

Figure 13: Amgen's biotech-biotech acquisition trail

Figure 14: Private equity M&A activity, 2009-2014

Figure 15: Issues in implementing M&A agreements

Figure 16: Joint venture agreements, 2009-2014

Figure 17: Recent joint ventures in the biopharma sector

Figure 18: Future trends in M&A in biopharma

Figure 19: Components of the acquisition deal structure

Figure 20: Components of the merger deal structure

Figure 21: Top M&A deals by value since 2009

Figure 22: Top merger deals by value since 2009

Figure 23: Most active M&A dealmakers Jan 2009- May 2014

Figure 24: Big pharma ' top 50 ' M&A deals 2009 to mid 2014

Figure 25: Big pharma M&A deal frequency - 2009 to mid 2014

Figure 26: Big biotech ' top 50 ' M&A deals 2009 to mid 2014

Figure 27: Big biotech M&A deal frequency - 2009 to mid 2014








>> Get this Report Now by email!Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93

If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require.

Product Formats Please select the product formats and the quantity you require.

Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________

Pharma and Biotech M&A Trends 2009-2014

1 User License--USD 2 995.00 Quantity: _____

CD-ROM--USD 3 495.00 Quantity: _____

2-5 User License--USD 4 495.00 Quantity: _____

Site License--USD 8 995.00 Quantity: _____

Corporate License--USD 14 995.00 Quantity: _____








>> Get this Report Now by email!Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card

Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer

Crédit Mutuel

RIB : 10278 07314 00020257701 89

BIC : CMCIFR2A

IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check

UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at

http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93

Customer signature:







Documents

Pharma and Biotech M&A Trends 2009-2014